Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
ILMN
Illumina
$82.24
Chart
$72 (+14.22%)
$86.62 (-5.06%)
$134.76 (-38.97%)
$108.66 (-24.31%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
ILMN
Illumina
Current Price
$82.24
Login to view Illumina (ILMN) recommendation from the last 90 days from financial news and social media.
Chart
$72 (+14.22%)
$86.62 (-5.06%)
$134.76 (-38.97%)
$108.66 (-24.31%)
ILMN Latest Headlines
Velsera Powers the Knowledgebase Behind Illuminas TSO Comprehensive Test Now Approved in Japan. BOSTON May 30 2025 /PRNewswire/ -- Velsera announces that its clinical Knowledgebase is powering the interpretation framework behind Illuminas TruSight™ Oncology Comprehensive (TSO Comp) assay which has received regulatory approval from Japans Ministry of Health Labour and Welfare...
Today
Illumina unveils PromoterAI a groundbreaking algorithm to accelerate insights for rare disease diagnosis. New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO May 29 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI a new AI algorithm that accurately...
Thu May 29, 2025
Broadcoms Private Cloud Outlook 2025 Report Reveals Definitive Cloud Reset. PALO ALTO Calif. May 29 2025 (GLOBE NEWSWIRE) -- Private clouds are no longer playing catch-up and public clouds are no longer the default as organizations recalibrate their cloud strategies. This cloud reset was the key takeaway from the Private Cloud Outlook 2025 report an in-depth global survey of 1800 senior IT leaders conducted by Illuminas in partnership with Broadcom Inc. (NASDAQ: AVGO). More than half (53%) of su
Thu May 29, 2025
Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032 | DelveInsight. Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032 |. DelveInsightThe AI in precision medicine market is experiencing significant growth driven by the increasing global prevalence of chronic and genetic disorders which has heightened the demand for personalized treatment approaches. This growth
Wed May 28, 2025
10.6% of VHT Holdings Seeing Recent Insider Buys. A look at the weighted underlying holdings of the Vanguard Health Care ETF (Symbol: VHT) shows an impressive 10.6% of holdings on a weighted basis have experienced insider buying within the past six months.Illumina Inc (Symbol: ILMN) which makes up 0.21% of the Vanguard Heal
Wed May 21, 2025
10.6% of VHT Holdings Seeing Recent Insider Buys. A look at the weighted underlying holdings of the Vanguard Health Care ETF (Symbol: VHT) shows an impressive 10.6% of holdings on a weighted basis have experienced insider buying within the past six months.Illumina Inc (Symbol: ILMN) which makes up 0.21% of the Vanguard Heal
Wed May 21, 2025
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software. ILMNs latest software features easy-to-use oncology apps enhanced multiomics pipelines and AWS F2 support enabling faster turnaround times.
Tue May 20, 2025
What 15 Analyst Ratings Have To Say About Illumina. Analysts'. ratings for Illumina (NASDAQ:) over the last quarter vary from ish to bearish as provided by 15 analysts.Summarizing their recent assessments the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.1581001000114000111002300Insights from analysts'. 12-month price targets are revealed presenting an average target of $108.07 a high estimate of $185.00 and a low estimate o
Tue May 20, 2025
What 15 Analyst Ratings Have To Say About Illumina. Analysts'. ratings for Illumina (NASDAQ:) over the last quarter vary from ish to bearish as provided by 15 analysts.Summarizing their recent assessments the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.1581001000114000111002300Insights from analysts'. 12-month price targets are revealed presenting an average target of $108.07 a high estimate of $185.00 and a low estimate o
Tue May 20, 2025
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450% JetBlue Holding Grow 90%. making bold moves from the lab to the tarmac.According to his latest 13F filing for the quarter ended March 31 the billionaire activist investor significantly boosted his holdings in ) and ) &. a striking bet on both biotech and airlines.Icahn increased his stake in Illumina by 450% adding 180000 shares to bring his total holding to 220000 shares. That holding now represents 0.25% of his $7 billion portfo
Fri May 16, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ILMN Stock trends
ILMN Stock performance
ILMN Stock analysis
ILMN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
